NCT01256775View on ClinicalTrials.gov

Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)

PHASE2CompletedINTERVENTIONAL
Enrollment

442

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Intermittent Claudication
Interventions
DRUG

NCX-4016

NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.

DRUG

NCX4016 placebo

NCX4016 placebo b.i.d. for 6 months

Trial Locations (1)

06126

Ospedale di Perugia, Perugia

Sponsors
All Listed Sponsors
lead

NicOx Research Institute S.r.l.

INDUSTRY